| [1] |
LU Renquan, LIU Guangyu, YANG Wentao, GUO Lin, GUAN Ming, SHAO Zhimin, XU Dazhi, NI Ming, TANG Feng, WANG Chaofu, LOU Jiatao, SUN Fenyong, XING Jinliang, PAN Yueyin.
Application consensus of peripheral blood HER2 gene amplification detection (digital PCR) in anti-HER2 therapy
[J]. China Oncology, 2022, 32(1): 90-96.
|
| [2] |
CONG Binbin, WANG Yongsheng.
Treatment landscape and challenges of managing the hormone receptor-positive early breast cancer
[J]. China Oncology, 2021, 31(8): 689-696.
|
| [3] |
GONG Chao , CHEN Kui , ZHANG Dekun , XIE Jingfeng , WU Fanghua , HUANG Yudian , XUE Yuqin , WANG Liqun .
Construction of a prediction model for metastasis in gastric cancer based on the weighted gene co-expression network analysis
[J]. China Oncology, 2021, 31(8): 746-753.
|
| [4] |
ZHU Yihui, LI Ting, HU Xichun.
Clinical research progress and prospect of trastuzumab deruxtecan
[J]. China Oncology, 2021, 31(8): 754-761.
|
| [5] |
DING Gaofeng, GUO Leiming, LU Yufei.
The relationship between expressions of HER2 and BRCA1 and radiotherapy sensitivity in breast cancer patients
[J]. China Oncology, 2021, 31(7): 589-595.
|
| [6] |
LIU Bin , ZHENG Pengyuan , MI Yang , REN Feifei , GAO Shuang , LIU Chuan , LI Fazhan .
Expression of LRP8 in gastric cancer and its significance in tumorigenesis
[J]. China Oncology, 2021, 31(4): 285-293.
|
| [7] |
WANG Chunjian , NIE Gang , MAO Yan .
The role of TRIP6 in breast cancer and its mechanism
[J]. China Oncology, 2021, 31(3): 161-169.
|
| [8] |
WANG Zhu, ZHANG Ying, ZHANG Jianwen, DENG Qiong, LIANG Hui.
Nuclear receptor HNF4α promotes castration-resistant prostate cancer via its regulation of androgen receptor expression
[J]. China Oncology, 2021, 31(3): 170-175.
|
| [9] |
ZHANG Yanjun, LI Jianchang, JIA Xiuhong, TIAN Chunmei.
Effects of FGFR inhibitor BGJ398 on cell biological behavior and drug resistance of leukemia cells
[J]. China Oncology, 2021, 31(3): 176-181.
|
| [10] |
GUO Ye , ZHANG Chenping .
Expert consensus on the treatment of recurrent/metastatic squamous cell carcinoma of the head and neck with anti-EGFR monoclonal antibody (2021 edition)
[J]. China Oncology, 2021, 31(12): 1220-1232.
|
| [11] |
YU Yi, CONG Qing, XU Congjian, JIANG Wei.
The effect of PAFR on cisplatin sensitivity in ovarian cancer cells and its mechanism
[J]. China Oncology, 2021, 31(11): 1063-1071.
|
| [12] |
PAN Jian, WEI Yu, YE Dingwei, ZHU Yao.
Correlation between EGFR (rs884419) gene polymorphism and clinicopathological characteristics of prostate cancer
[J]. China Oncology, 2021, 31(11): 1104-1109.
|
| [13] |
LIU Jiawei, LI Dan, ZHAI Qing.
Risk factors analysis of liver injury induced by chemotherapy in patients with breast cancer
[J]. China Oncology, 2021, 31(1): 52-62.
|
| [14] |
HE Xi, JIAO Xiaodong, ZANG Yuansheng.
Clinical research progress of tumor mutational burden in EGFR-mutant advanced non-small cell lung cancer
[J]. China Oncology, 2021, 31(1): 69-75.
|
| [15] |
ZHU Lihua , NI Tingting , FAN Xingwen , WU Kailiang .
Comparison of prognostic scoring systems in patients with EGFR-mutant lung cancer and brain metastases
[J]. China Oncology, 2020, 30(8): 605-610.
|
